SciBase Achieves Historic Coverage with Highmark, Transforming Dermatology Access

SciBase's Major Step Forward in U.S. Market

SciBase Holding AB, a frontrunner in advanced skin disease detection technology, announced a significant breakthrough with Highmark Blue Cross Blue Shield, one of the largest healthcare networks in the United States. This milestone comes as SciBase's innovative device, Nevisense, secures its first positive medical policy approval, an event that is expected to revolutionize the reimbursement landscape for dermatological care.

The inclusion of Nevisense in Highmark's covered services means that access to this state-of-the-art technology is no longer confined to private pay transactions. Eligible patients can now benefit from its clinical capabilities under a major U.S. insurer’s coverage plan. The shift not only embodies a pivotal point in SciBase's U.S. commercialization efforts but also aims to diminish financial obstacles that have historically limited broader clinical adoption of such essential technologies.

Pia Renaudin, CEO of SciBase, remarked, "This marks a defining milestone for our company and offers a substantial opportunity to scale our operations in the U.S. market. With Highmark on board as a payer, we can not only increase patient access but also expand the number of dermatology practices willing to implement Nevisense in their diagnostic toolkit."

The U.S. represents the largest commercial opportunity for SciBase, with an estimated 6,500 to 7,000 private dermatology clinics operational in the country. Specifically, around 6,000 of these clinics are considered relevant for Nevisense, which indicates a prime market for expansion. Notably, the annual number of skin biopsies performed exceeds 4 million, underscoring the demand for effective, non-invasive diagnostic technologies like Nevisense.

Impact of Highmark Coverage
The decision from Highmark is not merely about adding a new payer; it's a substantial step towards alleviating one of the key limitations faced in scaling commercial operations across the U.S. The pathway created by this coverage allows SciBase to leverage established clinical adoption into a broader, reimbursed utilization landscape.

For dermatologists, this change effectively reduces the financial barriers related to incorporating Nevisense into their standard patient care, thus making it easier for them to use this objective, non-invasive technology when assessing suspicious skin lesions.

The Highmark policy specifies that the Evaluation of Images for Suspicious Lesions (EIS) is considered medically necessary when a dermatologist encounters atypical pigmented lesions and is contemplating a biopsy. Certain criteria are established under the policy, including a focus on potential melanoma cases and specifications regarding the lesions' size and location.

This policy applies to all Highmark commercial insurance lines and self-funded employer groups, indicating a widespread impact on patient care. The endorsement of Nevisense by Highmark is supported by the National Comprehensive Cancer Network's Clinical Practice Guidelines for Cutaneous Melanoma, reassuring dermatology professionals of the device's clinical relevance and utility.

Looking Ahead
SciBase's engagement in the U.S. payer market is expected to continue, fostering additional commercial activity in regions where reimbursement is available. The company, with a solid foundation built on over two decades of research at Stockholm’s Karolinska Institute, is focused on advancing dermatological diagnostics.

As SciBase moves forward, its commitment to transforming how skin diseases are detected and prevented remains paramount. With innovative technology backed by increased patient accessibility and robust clinical guidelines, the company aspires to minimize patient suffering while enhancing healthcare outcomes across the board.

For those interested in the advancements within dermatological technology and healthcare, the developments from SciBase are certainly ones to watch as they forge ahead in creating healthier futures through early detection and intervention in skin pathology.